Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
HUTCHMED (China) Limited (HCM) Q4 2023 Earnings Call Transcript
01:25pm, Wednesday, 28'th Feb 2024
HUTCHMED (China) Limited (HCM) Q4 2023 Earnings Call Transcript
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
06:30am, Wednesday, 28'th Feb 2024
Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib) Sovleplenib for ITP accepted for NDA
Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
10:56am, Monday, 19'th Feb 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 75.1% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positi
Asure Partners with Key Benefit Administrators to Offer
12:11am, Friday, 16'th Feb 2024
AUSTIN, Texas, Feb. 15, 2024 (GLOBE NEWSWIRE) — Asure Software (NASDAQ: ASUR), a leading provider of cloud-based Human Capital Management (HCM) software solutions, is pleased to announce a strategic
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
07:00pm, Tuesday, 06'th Feb 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
03:30am, Friday, 02'nd Feb 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biophar
HUTCHMED to Announce 2023 Final Results
03:30am, Thursday, 01'st Feb 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for th
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
11:53pm, Monday, 29'th Jan 2024
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong —
Cancer drug developer Hutchmed aims to be sustainably profitable in 2025: CEO
12:48am, Monday, 13'th Nov 2023
Hutchmed's CEO and Chief Strategy Officer Weiguo Su explains the company's profit trajectory after its Takeda-partnered metastatic colorectal cancer drug received FDA approval.
Wall Street Analysts See a 107.24% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
11:16am, Tuesday, 03'rd Oct 2023
The mean of analysts' price targets for HUTCHMED (HCM) points to a 107.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Beware! 3 Machine Learning Stocks Waving Massive Red Flags Right Now
09:13am, Wednesday, 20'th Sep 2023
Though artificial intelligence and machine learning have gotten their fair share of hype this year, not all of these companies are positioned to outperform in 2023. This has led to the rise of machine
Hutchmed: Attractive Chinese R&D Giant
05:59pm, Friday, 11'th Aug 2023
Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company acts as a liaison between the healthcare systems o
HUTCHMED to Announce 2023 Half-Year Financial Results
04:30am, Monday, 26'th Jun 2023
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for
Wall Street Analysts See a 103.84% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
11:28am, Wednesday, 26'th Apr 2023
The consensus price target hints at a 103.8% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
All You Need to Know About HUTCHMED (HCM) Rating Upgrade to Buy
01:41pm, Monday, 10'th Apr 2023
HUTCHMED (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
